TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03240497

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cold Exposure
Description: The start of the training is scheduled 7 to 12 days before the endotoxemia experiment day. Subjects in this group will participate in a 4 day intensive cold exposure course (see section 5.1). On day 1, venous blood will be sampled directly after ice water immersion. On day 4, venous blood will be sampled before the training procedures on that day and after the last ice water immersion.~After the 4 day course, subjects will continue to practice cold exposure at home using cold showers. The timing and length of this training is analogous to the time spend on training in the cold in our previous study protocol \[7\].

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cold Exposure
Description: The start of the training is scheduled 7 to 12 days before the endotoxemia experiment day. Subjects in this group will participate in a 4 day intensive cold exposure course (see section 5.1). On day 1, venous blood will be sampled directly after ice water immersion. On day 4, venous blood will be sampled before the training procedures on that day and after the last ice water immersion.~After the 4 day course, subjects will continue to practice cold exposure at home using cold showers. The timing and length of this training is analogous to the time spend on training in the cold in our previous study protocol \[7\].

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength Ventilation
Description: The training is scheduled 2 to 6 days before the endotoxemia experiment day. Subjects in this group will receive a detailed, written instruction about the strength ventilation technique (see section 5.1). In addition, they will receive a 2 hour instruction session during which the research team will supervise the practices and clarify the instructions of needed. Subjects are instructed not to practice the learned techniques at home.
Study: NCT02939976

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multi-vessel Disease, Complete Revascularization
Description: Complete revascularization of all diseased arteries

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Resolute family of stents
Description: Revascularization with Medtronic Resolute family of stents in infarct related artery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Resolute family of stents
Description: Revascularization with Medtronic Resolute family of stents in infarct related artery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Resolute family of stents
Description: Revascularization with Medtronic Resolute family of stents in infarct related artery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Volcano based pressure wires Verrata, Verrata Plus and any subsequent marketed Volcano pressure wire technology
Description: Complete revascularization of all diseased arteries

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Terumo Glidesheath Slender
Description: Possible use of Terumo Glidesheath Slender

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Terumo Glidesheath Slender
Description: Possible use of Terumo Glidesheath Slender

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Terumo Glidesheath Slender
Description: Possible use of Terumo Glidesheath Slender

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Terumo TR Band Radial Compression Device
Description: Possible use of Terumo TR Band Radial Compression Device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Terumo TR Band Radial Compression Device
Description: Possible use of Terumo TR Band Radial Compression Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Terumo TR Band Radial Compression Device
Description: Possible use of Terumo TR Band Radial Compression Device
Study: NCT02539654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXE844 Sterile Otic Suspension, 0.3%

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tympanostomy Tube Insertion
Study: NCT03557476

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Octacosanol
Description: One capsules (20-mg) of 100% refined octacosanol powder from sugar cane (Swanson, Fargo ND, USA) was consumed twice a day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo pill was taken twice a day in a double-blinded method at the same frequency and time as the octacosanol supplement
Study: NCT02325245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin tablet 500 mg three times a day for 16 weeks. If there is no significant outcome obtained between two arms in 16 weeks, metformin will continue until 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo three times a day for 16 weeks. If there is no significant outcome obtained between two arms in 16 weeks, placebo will continue until 24 weeks.
Study: NCT02589353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Description: Acarbose solution will be swabbed on the tip of the tongue to inhibit salivary alpha amylase activity; each swab will contain \~484 microgram acarbose; total maximum exposure of each subject to acarbose will be \~14-30 mg each session (1-20 sessions)
Study: NCT04150068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Lenacapavir
Description: Tablets administered without regard to food

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Lenacapavir
Description: Tablets administered without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Lenacapavir
Description: Tablets administered without regard to food

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Lenacapavir Placebo
Description: Tablets administered without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous Lenacapavir
Description: Administered in the abdomen via subcutaneous injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Subcutaneous Lenacapavir
Description: Administered in the abdomen via subcutaneous injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous Lenacapavir
Description: Administered in the abdomen via subcutaneous injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Failing ARV Regimen
Description: Failing antiretroviral (ARV) regimen defined by the lack of efficacy. Any combination of approved and unapproved agents that could potentially be part of the failing regimen.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Failing ARV Regimen
Description: Failing antiretroviral (ARV) regimen defined by the lack of efficacy. Any combination of approved and unapproved agents that could potentially be part of the failing regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized Background Regimen (OBR)
Description: Optimized background regimen as prescribed by the Investigator
Study: NCT03240497

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength Ventilation
Description: The training is scheduled 2 to 6 days before the endotoxemia experiment day. Subjects in this group will receive a detailed, written instruction about the strength ventilation technique (see section 5.1). In addition, they will receive a 2 hour instruction session during which the research team will supervise the practices and clarify the instructions of needed. Subjects are instructed not to practice the learned techniques at home.
Study: NCT04593706

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone acetate + Betamethasone sodium phosphate
Description: the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone acetate + Betamethasone sodium phosphate
Description: the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone sodium phosphate
Description: the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar
Study: NCT04150068

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Optimized Background Regimen (OBR)
Description: Optimized background regimen as prescribed by the Investigator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized Background Regimen (OBR)
Description: Optimized background regimen as prescribed by the Investigator
Study: NCT01007292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM155
Description: intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: intravenous infusion
Study: NCT02839876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen
Description: Subject receives 1 g acetaminophen by the intravenous route every 6 hours for 4 doses beginning in the preoperative holding area.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral acetaminophen
Description: Subject receives 1 g acetaminophen by the oral route every 6 hours for 4 doses beginning in the preoperative holding area.
Study: NCT00312572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine transdermal patch applied for 7-day wear.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine transdermal patch applied for 7-day wear.
Study: NCT04593706

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone sodium phosphate
Description: the steroid will be injected to either a keloid or a 1.5 cm of the 11 cm hypertrophic scar
Study: NCT04222140

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ERIPTO Protocol
Description: combination biologic treatment

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BMAC Only
Description: BMAC treatment only
Study: NCT03362580

Intervention type: DEVICE
Intervention: Slit lamp examination
Description: The slit lamp is an instrument consisting of a high-intensity light source that can be focused to shine a thin sheet of light into the eye.Examination performed without pupil dilatation.

Intervention type: DEVICE
Intervention: Slit lamp examination
Description: The slit lamp is an instrument consisting of a high-intensity light source that can be focused to shine a thin sheet of light into the eye.Examination performed without pupil dilatation.

Intervention type: DEVICE
Intervention: Undilated 7-field color fundus photography
Description: Undilated 7-field color fundus photography with Cobra fundus camera. The examination will be done without pupil dilatation; but in case of very small pupils one drop of tropicamide will be instilled, after anterior segment observation with the slit lamp. Two ophthalmologists will assess fundus photos and OCT (Spectral domain optical coherence tomography) frames, to determine whether or not an ERM is present.

Intervention type: DEVICE
Intervention: Undilated 7-field color fundus photography
Description: Undilated 7-field color fundus photography with Cobra fundus camera. The examination will be done without pupil dilatation; but in case of very small pupils one drop of tropicamide will be instilled, after anterior segment observation with the slit lamp. Two ophthalmologists will assess fundus photos and OCT (Spectral domain optical coherence tomography) frames, to determine whether or not an ERM is present.

Intervention type: DEVICE
Intervention: Color scan
Description: Multicolor photo. The examination will be done without pupil dilatation; but in case of very small pupils one drop of tropicamide will be instilled, after anterior segment observation with the slit lamp.

Intervention type: DEVICE
Intervention: Color scan
Description: Multicolor photo. The examination will be done without pupil dilatation; but in case of very small pupils one drop of tropicamide will be instilled, after anterior segment observation with the slit lamp.

Intervention type: DEVICE
Intervention: Spectral domain optical coherence tomography
Description: Spectral domain optical coherence tomography (OCT) with Heidelberg Retina Tomography device. The examination will be done without pupil dilatation; but in case of very small pupils one drop of tropicamide will be instilled, after anterior segment observation with the slit lamp.Two ophthalmologists will assess fundus photos and OCT frames, to determine whether or not an ERM is present.

Intervention type: DEVICE
Intervention: Spectral domain optical coherence tomography
Description: Spectral domain optical coherence tomography (OCT) with Heidelberg Retina Tomography device. The examination will be done without pupil dilatation; but in case of very small pupils one drop of tropicamide will be instilled, after anterior segment observation with the slit lamp.Two ophthalmologists will assess fundus photos and OCT frames, to determine whether or not an ERM is present.
Study: NCT03027323

Intervention type: DEVICE
Group type: OTHER
Intervention: AxoTrack System
Description: The AxoTrack system is a novel ultrasound guidance system intended to facilitate central venous cannulation (CVC) by a single operator as well as to reduce complications and time associated with CVC. The AxoTrack has a small ultrasound scan head which facilitates imaging of the subclavian vein.
Study: NCT03345628

Intervention type: DRUG
Intervention: Sedatives
Description: sedated group received sedative drugs to tolerated intubation and ventilation
Study: NCT00715845

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carbon dioxide insufflation
Description: For baseline evaluations, all patients will undergo a battery of neuropsychological testing after obtaining written informed consent and before cardiac surgery. A transesophageal echocardiography and a transcranial doppler will be performed for intraoperative evaluations. For post-operative evaluations, patients will undergo a diffusion-weighted magnetic resonance imaging three to seven days after surgery and have a repeat neuropsychological assessment at six to eight weeks post cardiac surgery. All patients will undergo cardiopulmonary bypass using the same equipment and technique. Patients in both groups will receive a jackson-pratt drain as a gas diffuser. The jackson-pratt drain will be placed 5 cm below the cardiothoracic wound opening adjacent to the diaphragm and if the patient is randomized to carbon dioxide, the flow will be set at 2 litre/min.
Study: NCT02918643

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Use of an application to for mobile devices like decision-making support for prescription drugs to elderly patients

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Use of an application to for mobile devices like decision-making support for prescription drugs to elderly patients
Study: NCT03976414

Intervention type: OTHER
Intervention: eMOM
Description: The intervention is the use of the website (eMOM), which is the electronic adaption of the program, Mind Over Matter: Healthy Bowels, Healthy Bladder (MOM), a small-group, community-based health promotion program that builds skills and self-efficacy to make behavior changes that improve urinary and bowel symptoms among older women with incontinence.
Study: NCT00964015

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6% Hydroxyethyl Starch 130/0.4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Normal Saline
Study: NCT03453112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foster 100/6mg NEXThaler
Description: Fixed combination of beclomethasone dipropionate 100mg plus formoterol fumarate 6mg per actuation as inhalation powder with a new dry powder inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foster 100/6mg pMDI
Description: Fixed combination of beclomethasone dipropionate 100mg plus formoterol fumarate 6mg per actuation as pMDI with HFA_134a propellant
Study: NCT01178814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid (Lenalidomide)
Description: The starting dose will be 10 mg days 1-28 with the first dose reduction going to 5 mg days 1-28 of a 28 day cycle. Therapy will cease if there is no response after 12 weeks.
Study: NCT02003456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cardiac PET scan w/18F-Fluorodeoxyglucose and rubidium-82
Description: Study subjects will undergo a Cardiac PET scan that will take approximately 20 minutes to complete. In addition to standard clinical rubidium-82/18F-fluorodeoxyglucose (FDG) PET imaging, during a separate imaging session, participants will be infused with a second dose of the radio-tracer rubidium-82 during FDG imaging scan that will take an additional 10 to 15 minutes to complete.
Study: NCT02716766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: IV
Study: NCT01752634

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Secukinumab (AIN457)
Description: Secukinumab (AIN457)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab (AIN457)
Description: Secukinumab (AIN457)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab (AIN457)
Description: Secukinumab (AIN457)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab (AIN457)
Description: Secukinumab (AIN457)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo PFS for s.c. administration.
Study: NCT00957905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvocidib Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvocidib Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study: NCT01294748

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiStent DES
Description: The MiStent is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endeavor DES
Description: The Endeavor is a device/drug combination comprised of two components; a stent and a drug product (everolimus within a durable polymer coating).
Study: NCT01048905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Glutamine
Description: Oral L-glutamine 10 grams TID or (0.1g/kg TID) for children \< 15 years of age.
Study: NCT00898326

Intervention type: OTHER
Intervention: biopsy
Description: Conduct prostatic needle biopsy at 36-39 months-after brachy therapy. Basic method is by transectal ultra-sound-guided systematic biopsy,; systematic sextant biopsy which involves samples from both seminal vesicles is adopted as much as possible.
Study: NCT04247568

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Listening to an audiotape
Description: The participants listen to a audiofile that consists of hypnosis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listening to an audiotape
Description: The participants listen to a audiofile that consists of hypnosis
Study: NCT04657367

Intervention type: OTHER
Intervention: Observational study - registry
Description: Observational study - registry

Intervention type: OTHER
Intervention: Observational study - registry
Description: Observational study - registry

Intervention type: OTHER
Intervention: Observational study - registry
Description: Observational study - registry
Study: NCT02977728

Intervention type: OTHER
Intervention: Olfactory Evaluation
Description: The investigators will evaluate the olfactory system of all participants by the use of the Sniffin'Sticks batterie

Intervention type: OTHER
Intervention: Olfactory Evaluation
Description: The investigators will evaluate the olfactory system of all participants by the use of the Sniffin'Sticks batterie
Study: NCT04691206

Intervention type: OTHER
Group type: OTHER
Intervention: briefing objectives, intraoperative teaching, and debriefing feedback
Description: A standardized step-wise operative curriculum amongst general surgeons will be implemented among all general surgery residents. Residents will follow and graduate through this curriculum by initiating a perioperative model of briefing objectives, intraoperative teaching, and debriefing feedback (BID).
Study: NCT04039321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ESPB group
Description: USG probe will be placed in a longitudinal parasagittal orientation 3 cm lateral to T7 spinous process. The erector spinae muscles will be identified hyperechoic transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 21-gauge 10-cm needle was inserted using an in-plane superior-to-inferior approach or an outplane approach. Following confirmation of the correct position of the needle with 5 ml normal saline, a dose of 20 ml %0.25 bupivacaine will be administered. The same procedure will be performed at the other site (totally 40 ml %0.25 bupivacaine). Standard pain follow up and monitorization will be performed.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: The patients in this group will be performed no block. Standard pain follow up and monitorization will be performed.
Study: NCT01565798

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Copper-alloy surfaced patient care objects
Description: Copper-alloy surfaced bed rails, over bed tray tables, chair arms, nurse call devices, laptop and computer monitor bezels, and IV poles were placed into the patient ICU rooms.
Study: NCT04587024

Intervention type: OTHER
Group type: OTHER
Intervention: mHealth intervention
Description: Subjects will receive mHealth direct observation of therapy for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard of care
Description: Subjects will receive standard of care observation for 12 weeks